tak-573
mAbexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 4, 2017 (NCT03215030)
Timeline
2010s
- Jan 1, 2017
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Lymphocyte differentiation antigen CD38Supplementation
CD38 supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297836 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05590377 | Phase 1/Phase 2 (Phase 2) | Jan 3, 2023 | Takeda |
| NCT05556616 | Phase 1 | Oct 27, 2022 | Takeda |
| NCT04392648 | Phase 1 | Jun 24, 2020 | Takeda |
| NCT04157517 | Phase 1 | Dec 13, 2019 | Millennium Pharmaceuticals |
| NCT03215030 | Phase 1/Phase 2 (Phase 2) | Oct 4, 2017 | Millennium Pharmaceuticals |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Takeda | For profit | 3 | 3 | 2 | 2020 |
| Millennium Pharmaceuticals | For profit | 2 | 2 | 2 | 2017 |
2 organizations
Page 1 / 1